Study Overview: This research involves a new drug called *rademikibart*, which will be tested on people with asthma and type 2 inflammation. It is a Phase 2 trial, meaning it's being tested for effectiveness and safety. Participants will either receive rademikibart with their usual asthma treatment or a placebo (a fake pill) plus their usual treatment. This study is designed to see if rademikibart helps during an asthma attack.

Key Points:

Participants must have been diagnosed with asthma for at least a year and have had at least one serious asthma attack in the past.

Participants cannot join if they use certain medications regularly, have heart issues, or have a history of smoking.

This study requires an urgent healthcare visit during an asthma attack to participate.

Eligibility involves having specific blood markers related to type 2 inflammation, such as high eosinophil counts (a type of white blood cell). People with certain health conditions or behaviors, like heart problems or smoking, cannot join this study. Women who are pregnant or breastfeeding are also excluded.